Clinical Trial Detail

NCT ID NCT03042611
Title Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors LSK BioPartners Inc.
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Rivoceranib

Age Groups: adult senior

No variant requirements are available.